FLT3-ITD analysis using high-sensitivity PCR-NGS. (A-B) Kaplan-Meier estimate of RFS (A) and OS (B) according to postinduction FLT3-ITD MRD status assessed by PCR-NGS. (C) Kaplan-Meier estimate of RFS according to postinduction FLT3-ITD MRD status and treatment arm. (D) Scatter plot distribution of FLT3-ITD MRD after induction as indicated by variant allele frequency according to treatment arm and remission status. (E) FLT3-ITD status at relapse assessed by CE among patients in the sorafenib and placebo arms. Seven patients without available CE results at relapse were not included. (F) Presence of FLT3-ITD microclones with variant allele frequency (VAF) ≤ 1% in sorafenib-treated patients at relapse assessed by PCR-NGS. LLD, lower limit detection < 0.001%.